Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports Second Quarter 2022 Financial Results Aug 04, 2022 Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets Jul 26, 2022 Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer Jul 01, 2022 Nektar Therapeutics Reports First Quarter 2022 Financial Results May 05, 2022 Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Apr 25, 2022 Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® Apr 23, 2022 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan Apr 22, 2022 Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) Apr 14, 2022 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Mar 14, 2022 Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma Mar 14, 2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »